Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Patent
1998-07-22
2000-10-31
Johnson, Nancy A.
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
5303871, 5303881, 53038885, 5303891, C07K 1618, C07K 1628, C07K 1632
Patent
active
06140473&
ABSTRACT:
The present invention relates to somatic mutations in the Multiple Tumor Suppressor (MTS) gene in human cancers and their use in the diagnosis and prognosis of human cancer. The invention further relates to germ line mutations in the MTS gene and their use in the diagnosis of predisposition to melanoma, leukemia, astrocytoma, glioblastoma, lymphoma, glioma, Hodgkin's lymphoma, CLL, and cancers of the pancreas, breast, thyroid, ovary, uterus, testis, kidney, stomach and rectum. The invention also relates to the therapy of human cancers which have a mutation in the MTS gene, including gene therapy, protein replacement therapy and protein mimetics. Finally, the invention relates to the screening of drugs for cancer therapy.
REFERENCES:
Serrano, m. et al. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature, 366:704-707, Dec. 1993.
Current Protocols in Molecular Biology, vol. 2 Ed. F.M. Ausubel, John Wiley & Sons, New York, pp. 11.15.15-11.15.4, 1990.
Lin, M.C. et al. Structure-function relationships in glucagon: properties of highly purified Des-His 1-, Monoidodo-, and [Des-Asn28, Thr29](homoserine lactone27)-glucagon. Biochemistry, 14(8): 1559-1563, 1975.
Burgess, W.H. et al. Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue. J. Cell Biol., 111: 2129-2138, Nov. 1990.
Galfre, G. and Milstein, C. Preparation of monoclonal antibodies: strategies and procedures. Methods in Enzymology, 73: 3-46, 1981.
Stone et al., Complex Structure and Regulation of the P16 (MTS1) Locus, Cancer Research, vol. 55, pp. 2988-2994, Jul. 15, 1995.
Hannon et al., p15.sup.ink4B is a Potential Effector of TGF-.beta.-induced Cell Cycle Arrest, Nature, vol. 371, pp. 257-260, Sep. 15, 1994.
Guan, K-L. et al., Growth suppression by p18, a p16INK/MTS1-and p14INK4B/MTS2-related DCK6 inhibitor, correlates with wild-type pRb function, Genes & Development, vol. 8, 2939-2952, Dec. 15, 1994.
Stone et al., Genomic Structure, Expression and Mutational Analysis of the P15 (MTS2) Gene, Oncongene, vol. 11, pp. 987-991, 1995.
Jiang et al., Comparative Analysis of Homo sapiens and Mus Musculus Cyclin-Dependent Kinase (CDK) Inhibitor Genes P16 (MTS1) and P15 (MTS2), Jour. Mol. Evol., vol. 41, pp. 795-802, 1995.
Sherr, Cancer Cell Cycles, Science, vol. 274, pp. 1672-1677, Dec. 6, 1996.
Holleran Anne L.
Johnson Nancy A.
Myriad Genetics Inc.
LandOfFree
Antibodies specific for MTS2 Polypeptide does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies specific for MTS2 Polypeptide, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies specific for MTS2 Polypeptide will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2053419